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Trapidil (N,N-diethyl-5-methyl[l,2,4]triazolo[l,5-cu]pyrimidine-7-amine) inhibits platelet spreading and 
aggregation induced by arachidonic acid (AA), a stable analogue of prostaglandin (PG) endoperoxides 
(U46619), ADP, and low concentrations of thrombin, but not by A23187 and high concentrations of 
thrombin. Trapidil does not affect platelet adenylate cyclase but inhibits the CAMP PDE by approx. 50%. 
PDE inhibition proceeds via a competitive mechanism (K1 = 0.52 mM) and is not mediated by calmodulin 
inhibition. Trapidil does not change the platelet basal CAMP level but potentiates an increase of CAMP 
induced by the stable prostacyclin analogue (68PGIr). These results suggest that trapidil antiplatelet 
effects may be due to the inhibition of platelet PDE. 
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1. INTRODUCTION 
An important property of cardiovascular drugs 
is their ability to inhibit platelet function and thus 
prevent the formation of intravascular occlusive 
and mural thrombi. It was previously demon- 
strated that an antianginal drug, trapidil, inhibits 
various platelet reactions: (i) aggregation in sus- 
pension [1,2]; (ii) spreading on a collagen-coated 
surface [3]; (iii) formation of surface-bound 
thrombi-like aggregates (31. The mechanism of 
trapidil antiplatelet effects remains obscure. It was 
established that trapidil decreases the formation of 
TXA2, a proaggregatory AA metabolite in plate- 
lets [l-3]. However, the antiplatelet properties of 
trapidil cannot be explained only by the inhibition 
of TXAz synthesis since: (i) trapidil completely 
blocks platelet aggregation and spreading induced 
by U46619 [l-3], a stable PG endoperoxide ana- 
logue which is not converted to TXA2 and does not 
induce TXA2 synthesis in platelets [4]; (ii) quanti- 
tative correlation between trapidil effects on AA- 
induced platelet aggregation/spreading and TXA2 
formation is absent [3]. A platelet cyclic nucleotide 
system which plays an important role in the regula- 
tion of their activity [5] may be another site of 
trapidil action. It was demonstrated that trapidil 
inhibits the activity of CAMP PDE in heart muscle 
161. 
2. MATERIALS AND METHODS 
2.1. Platelet isolation 
Abbreviations: AA, arachidonic acid; PG, prostaglan- 
din(s); TXA2, thromboxane AZ; PDE, phosphodiester- 
ase; PRP, platelet-rich plasma 
Blood was drawn from the antecubital vein of 
healthy donors. To obtain PRP for platelet ag- 
gregation experiments 3.8% Na citrate was used as 
anticoagulant (1 vol. anticoagulant : 9 vols blood); 
to obtain PRP for washed and gel-filtered platelet 
preparations acid-citrate-dextrose (1 vol. an- 
ticoagulant :6 vols blood) [7] was used. The PRP 
was prepared by centrifugation of anticoagulated 
blood at 150 x g for 12.5 min, platelet-poor 
plasma, by repeated centrifugation (after removing 
PRP) at 1000 x g for 20 min. Washed platelets 
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were isolated as in [7] using Tyrode solution (pH 
6.5); gel-filtered platelets were obtained as in [8]. 
In both cases, platelets were finally suspended in 
Tyrode solution containing 2 mM Ca’+, 1 mM 
Mg2+, and 0.35% bovine serum albumin (pH 
7.35). 
2.2. Platelet aggregation 
Platelet aggregation was performed using a two- 
channel Payton aggregometer at 37°C a stirring 
rate of 900 rpm, and platelet count of 2 x 108/ml. 
The aggregation induced by AA, ADP and U466 19 
was measured in PRP; aggregation induced by 
A23187 and thrombin was measured in the suspen- 
sion of washed platelets. The level of aggregation 
was determined as the maximal light transmission 
3-5 min after the addition of the inducer. 
2.3. Platelet adhesion to the collagen-coated 
surface 
Platelet adhesion was carried out in 16.4-mm 
wells of culture plates (Falcon) coated with fibrillar 
calf skin collagen [9]. Gel-filtered platelets (2-4 x 
107) in 200~1 Tyrode solution, with or without 
trapidil, were introduced into each well with subse- 
quent addition of AA, U46619 or thrombin [3,10]. 
The area covered with spread platelets and the 
number of thrombi-like aggregates on the collagen 
substrate were determined by scanning electron 
microscopy [3, lo]. 
2.4. Determination of platelet cAMP 
One ml washed platelets (4-5 x 10’) was placed 
into the aggregometer cuvette and incubated with 
Tyrode solution or trapidil at 37°C and a stirring 
rate of 900 rpm. In some experiments, 6;P-PGII 
was added to platelets 30 s after buffer or trapidil. 
One min after the last addition, 2 ml of 96% 
ethanol, preheated to 7O”C, was introduced into 
the cuvette. After centrifugation, the supernatant 
was removed and the liquid phase was evaporated 
under vacuum. The pellet was dissolved in 0.05 M 
Tris-HCl, 4 mM EDTA (pH 7.5), and CAMP was 
determined by the high-affinity protein binding 
assay [ll]. 
2.5. Determination of platelet membrane 
adenylate cyclase 
Platelet membranes were isolated as in [12] as 
modified in 1131. To determine the activity of 
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adenylate cyclase, 5-10 pg membrane protein were 
incubated for 10 min at 30°C in 50 ~1 medium con- 
taining 50 mM triethanolamine, 30 mM Tris- 
HCI, 0.3 mM EGTA, 2 mM MgClz, 1 mM 3-iso- 
butylmethylxanthine, 1 mM dithiothreitol, 30 PM 
dl-propranolol, 25 pug creatine kinase (over 100 
units/probe), 5 mM creatine phosphate, 50pM 
ATP, 10 PM GTP, 0.1 mM CAMP, and 0.2-0.5 
pCi [GJ-~‘P]ATP (pH 7.4). ]32P]cAMP formation 
was determined as in 1141. 
2.6. Determination of CAMP PDE activity in 
platelet homogenate and purified rabbit heart 
PDE preparation 
Platelet homogenate was obtained by freeze- 
thawing. PDE from rabbit heart was isolated as in 
[15] and calmodulin as in [16]. To determine 
CAMP activity, 40 rug platelet homogenate protein 
or 2Opg PDE preparation protein were incubated 
for 10 min at 30°C in 50~1 medium containing 
20 mM imidazole, 5 mM MgCL, l-10pM CAMP 
and O-2-0.3 ,Ki 13H]cAMP (pH 7.4). In some ex- 
periments, Ca’+, EGTA and calmodulin were add- 
ed to the incubation medium. [3H]AMP formation 
was determined as in 1171. 
3. RESULTS 
Trapidil at 1 mM almost completely prevents 
platelet aggregation in suspension induced by AA, 
U46619, ADP and low concentrations of throm- 
bin. Trapidil is less effective when more potent in- 
ducers, high thrombin concentrations and the Ca2+ 
ionophore A23 187 are used (table 1). Trapidil also 
inhibits the reactions specific for platelet-sub- 
strate interactions: spreading of platelets and for- 
mation of thrombi-like aggregates on the sheets of 
spread platelets [lo]. It was shown using scanning 
electron microscopy that trapidil prevents the 
spreading and formation of thrombi-like ag- 
gregates on the collagen substrate induced by AA, 
U46619 and low, but not high concentrations of 
thrombin (table 1). 
Trapidil at a concentration which inhibits 
platelet activation in suspension and on the surface 
does not change the basal platelet CAMP level 
(fig. 1A). However, trapidil potentiates the increase 
of CAMP induced by the stable prostacyclin 
analogue 6,&-PGIr by approx. 40% ffig.lB). 
Trapidil does not affect the adenylate cyclase of 
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Trapidil effects on platelet aggregation in suspension, platelet spreading and formation of thrombi- 
like aggregates on a collagen substrate 
Inducer 
Aggregation 
in suspension 
Inhibition (70) 
Thrombi-like 
aggregate 
formation 
Spreading 
AA (lOO-200~M or 1 mM)e 100.0 -t 1.6a (3) 100 * oa (4) 96.3 + l.Oa (9) 
U46619 (l-2pM) 100.0 * oa (4) 100 + Ob (4) 96.9 + l.Oa (4) 
ADP (10pM) 82.4 + 1.6b (3) nd. n.d. 
Thrombin (0.1-0.2 units/ml) 89.2 + 7.7b (5) 72.7d (1) 76.Sd (1) 
Thrombin (l-2 units/ml) 7.0 + 4.2d (4) 20.2 2 7.1d (2) 13.0 + 7.6d (2) 
A23187 (OS-l.0 PM) 23.0 + 5.1’ (8) n.d. n.d. 
Platelet aggregation in suspension was determined in an aggregometer; surface-bound thrombi-like 
aggregate formation and platelet spreading by scanning electron microscopy [3]. Inhibitory effects 
of trapidil (1 mM) were calculated with respect to the corresponding controls. The data represent 
the means +- SE; the number of experiments is given in brackets. Significance of the inhibitory 
effects was calculated using Student’s paired f-test for n > 2. a p < 0.001, b p < 0.01, ’ p < 0.05, 
d not significant. e Aggregation in PRP. n.d., not determined 
platelet membranes. Its activity was 39.1 + 1.8 and 
38.1 f 1.6 pmol cAMP/min per mg membrane 
protein in the absence and presence of 1 mM 
trapidil, respectively (mean + SE, n = 5). 
Investigation of the trapidil effect on the activity 
of CAMP PDE was carried out in comparison with 
a well-known PDE inhibitor, theophylline [18]. 
Fig.1. Effects of trapidil on the basal (A) and stimulated 
(by 3 mM @-PGIi) (B) levels of platelet CAMP. Platelets 
were incubated in the absence (hatched bars), or 
presence (filled bars) of 1 mM trapidil. The data 
represent he means k SE (n = 6). The significance of the 
differences between the means was determined using 
Student’s t-test. ***p < 0.001. 
Since both Ca2+-calmodulin-dependent and -inde- 
pendent forms of PDE exist [19], the activity of 
platelet PDE was measured in the presence and 
absence of Ca’+ and calmodulin. As seen from 
table 2, PDE activity increases following Ca2+ ad- 
dition and is hardly stimulated by exogenous 
calmodulin. These results indicate the presence of 
Table 2 
Effects of trapidil and theophylline on the activity of 
platelet CAMP PDE 
Inhibitor CAMP PDE activity 
- Calmodulin + Calmodulin 
+ EGTA + Ca2+ + EGTA + Ca’+ 
None 269+11 38OklO 305+_10416+ 1 
Trapidil 
(1 mM) 165 +- 2 192 + 12 164 +- 3 209 + 11 
Theophylline 
(1 mM) 143 f 9 196 +- 14 156 k 7 228 * 21 
CAMP PDE activity was determined at 10pM CAMP. 
Additions: calmodulin (20 PM), EGTA (1 mM) and 
Ca2’ (1 mM). The data represent he means + SE (n = 
3). Significance of the inhibitory effects of trapidil and 
theophylline was calculated using Student’s t-test for 
means. In all cases p < 0.01 
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I/CAMP. M-’ 
Fig.2. Inhibition of a purified PDE from rabbit heart by 
trapidil. The data are given in a double-reciprocal plot. 
Incubation was carried out without (0) or with (0) 
I mM trapidil. Means + SE (n = 3). 
endogenous calmodulin in the preparation. 
Trapidil inhibits PDE activity equally (by approx. 
50%) in both the presence and absence of Ca2’ and 
calmodulin (table 2). Trapidil inhibits PDE as ef- 
fectively as the same concentration of theophyliine 
(table 2). 
To study the mechanism of the trapidil effect on 
PDE, a purified preparation of PDE from rabbit 
heart was used. It was shown that trapidil inhibits 
PDE via a competitive mechanism with K = 
5.24 x 10m4 M (fig.2). The Ki of trapidil is similar 
to that of theophylline which is also a competitive 
PDE inhibitor [18]. 
4. DISCUSSION 
The study of trapidil effects on the platelet 
CAMP system presented here allows us to explain 
its antiplatelet action by the inhibition of PDE. It 
has been demonstrated that trapidil does not affect 
the activity of adenylate cyclase but inhibits the 
CAMP PDE activity of human platelets. The in- 
hibition of PDE proceeds via a competitive 
mechanism which is, apparently, accounted for by 
the structural similarity between trapidil and the 
adenyl ring of CAMP. The inhibitory activity of 
trapidil is similar to that of theophylline. Trapidil, 
like other PDE inhibitors [20], does not change the 
basal total cAMP Ieveis in platelets but additionaI- 
ly stimulates an increase in CAMP during the ac- 
tivation of adenylate cyclase by 6@-PGI*. The 
absence of PDE inhibitor effects on the basal total 
CAMP level is attributed to the existence of two 
CAMP pools. The active pool is only a small frac- 
tion of the total one [20]. Thus, trapidil and other 
PDE inhibitors can prevent the activation of 
platelets by affecting only the functionally active 
pool without increasing the total CAMP level in 
platelets. 
The previousfy discovered decrease of TXAz 
synthesis in platelets in the presence of trapidil 
II-31 may also be explained by the influence on 
PDE. It was shown that a PDE inhibitor, 
dipyridamole, causes approximately the same 
decrease in TXA;? formation in platelets as trapidil 
[21], The inhibitory effect of trapidil is manifested 
onIy in whole platelets and disappears in platelet 
homogenates [ll. These results suggest hat trapidil 
itself does not affect the activity of enzymes par- 
ticipating in AA metabolism. Probably its effect 
on TXAZ synthesis is mediated by the action on the 
cyclic nucleotide system. 
Activity of CAMP PDE in platelets is increased 
in the presence of Ca2+ and calmodulin. It is 
known that calmodulin regulates the activity of 
PDE and many other enzymes and processes in 
platelets 1221. TrapidiI equally inhibits PDE activi- 
ty in both the presence and absence of Ca2+ and 
calmoduhn. Unlike specific calmodulin inhibitors 
[22,23] trapidil effectively prevents the activation 
of platelets induced only by relatively weak in- 
ducers, but not by the Ca2+ ionophore A23187 and 
high concentrations of thrombin. We also failed to 
demonstrate the interaction of trapidil with 
calmodulin (not shown). These results suggest hat 
antiplatelet effects of trapidil are not mediated by 
calmodulin inhibition. 
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